KNSA stock forecast
Our latest prediction for Kiniksa Pharmaceuticals Ltd.'s stock price was made on the May 29, 2018 when the stock price was at 17.21$.
In the short term (2weeks), KNSA's stock price should outperform the market by 5.60%. During that period the price should oscillate between -2.42% and +4.31%.
In the medium term (3months), KNSA's stock price should outperform the market by 9.62%. During that period the price should oscillate between -5.37% and +12.48%.Get email alerts
About Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a profit of 3.69$ per share.
The book value per share is 6.91$
Three months stock forecastMay 29, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|